Belgium· BE-AMP-SAM568613-00
Hepcludex 2 mg
A bulevirtide product containing bulevirtide acetate, registered in Belgium by Gilead Sciences Ireland UC. The same ATC class is registered in 14 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Bulevirtide is registered in 14 of 19 countries.
Countries holding a registration under ATC J05AX28 (bulevirtide), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 10 of them publish a price we can compare per daily dose
Bulevirtide · ATC J05AX28
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of bulevirtide costs, country by country.
Normalised to the WHO defined daily dose (2 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Bulevirtide · price per daily dose (2 mg)
USD · FX 28 Sept 2026
- CH Switzerland$219.16
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Bulevirtide Acetate
- Manufacturer
- Gilead Sciences Ireland UC
- Country
- Belgium (BE)
- ATC code
- J05AX28
- ATC class
- Bulevirtide
- Defined daily dose
- 2 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bulevirtide in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/804d2bbc-e2e9-4673-bfc0-599dedd460e9 GET /v1/drugs/804d2bbc-e2e9-4673-bfc0-599dedd460e9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Hepcludex 2 mg",
"name_fr": "Hepcludex 2 mg",
"name_nl": "Hepcludex 2 mg",
"amp_code": "SAM568613-00",
"strengths": [
"2.0000"
],
"pack_count": 1,
"substances": [
"Bulevirtide Acetate",
"Bulevirtide",
"Mannitol",
"Sodium Carbonate Anhydrous",
"Sodium Hydrogen Carbonate",
"Sodium Hydroxide"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Bulevirtide",
"authorisation_numbers": [
"EU/1/20/1446/001"
]
}See everything about bulevirtide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.